Expression pattern and prognostic implication of SALL4 gene in myeloid leukemias: a case-control study. 
SALL4 is a transcription factor that retains stem cells in an undifferentiated state and promotes its self-renewal.  In addition, it is implicated in leukemogenesis via its effect on leukemic stem cells.  This study aimed to characterize the expression pattern of SALL4 gene in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) at different progression phases of the leukemic process and to assess its prognostic significance.  Real-time PCR was used in 106 patients: 54 AML patients; 43 de novo and 11 in complete remission (CR), 52 CML patients; 31 in chronic phase (CP), 11 in deep molecular response (MR4) and 10 in accelerated/blastic phase (AP/BP); and in 21 nonmalignant bone marrow samples.  SALL4 gene expression was elevated in AML, AML-CR and CML-CP (median = 5.180, 4.604 and 14.125 fold changes, respectively).  Elevated SALL4 gene expression among AML de novo patient was associated with poor disease-free survival (DFS) rates (p = .022).  Among CML patients, the highest percentage of patients with a high SALL4 (p = .033) was among CML-CP.  SALL4 has a role in leukemogenesis; high SALL4 expression was associated with poor DFS among AML patients.